Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On February 3, 2023, Barbara Duncan was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the "Company"). Ms. Duncan was elected to the class of directors with terms ending at the Company's annual meeting of stockholders in 2024. Ms. Duncan was initially assigned to serve on the Audit Committee. Ms. Duncan will receive compensation for her services (currently consisting of cash retainers for Board and committee service and restricted stock awards) under our director compensation program applicable to all non-employee directors, as revised from time to time. The current components of the non-employee director compensation program were described in our proxy statement for the 2022 Annual Meeting of Stockholders held on May 5, 2022.

There are no arrangements or understandings pursuant to which Ms. Duncan was elected as a director and there are no related person transactions between the Company and Ms. Duncan.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses